CTMX Shares Outstanding History
Below is a table of the CTMX shares outstanding history going back to 10/8/2015:

Date CTMX Shares Outstanding
10/8/201534.92M
11/19/201536.02M
3/2/201636.08M
5/4/201636.09M
8/1/201636.29M
11/1/201636.40M
2/28/201736.52M
3/17/201736.57M
5/3/201736.75M
8/4/201736.87M
11/3/201738.41M
3/5/201838.61M
5/7/201838.96M
8/6/201844.96M
11/2/201845.01M
1/31/201945.11M
4/30/201945.31M
7/31/201945.41M
10/31/201945.43M
1/31/202045.57M
4/30/202045.92M
7/31/202046.19M
10/31/202046.22M
2/2/202164.78M
4/30/202165.01M
7/31/202165.16M
10/31/202165.25M
1/31/202265.39M
4/29/202265.40M
7/29/202265.95M
10/31/202266.08M

Also see: CTMX Market Cap History
CTMX YTD Return
CTMX Historical Shares Outstanding:
+9.44% CAGR
CTMX Historical Shares Outstanding: +9.44% CAGR

Mouse over chart for data details
10/8/2015 ...10/31/2022
CytomX Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company. Co. is developing an antibody-based therapeutics created using its Probody® therapeutic technology platform. Co.'s products include: Praluzatamab ravtansine, which is an activated antibody-drug conjugates directed against CD166, a tumor target previously considered undruggable due to its high expression on normal tissues; CX-2029, which opens a therapeutic window for targeting CD71; Pacmilimab, which is a Probody therapeutic against PD-L1, a clinically and commercially validated cancer target; and BMS-986249 and BMS-986288, which is the Probody versions of ipilimumab. We show 31 historical shares outstanding datapoints in our coverage of CTMX's shares outstanding history.

Understanding the changing numbers of CTMX shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like CTMX versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching CTMX by allowing them to research CTMX shares outstanding history as well as any other stock in our coverage universe.
Quotes delayed 20 minutes

Email EnvelopeFree CTMX Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Shares Outstanding Importance


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
CytomX Therapeutics (CTMX) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:

CTRV Shares Outstanding History
CTSO Shares Outstanding History
CTXR Shares Outstanding History
CUE Shares Outstanding History
CUR Shares Outstanding History
CUTR Shares Outstanding History
CVRX Shares Outstanding History
CVS Shares Outstanding History
CWBR Shares Outstanding History
CYCC Shares Outstanding History
More Healthcare companies »

 

CTMX Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2023, All Rights Reserved

Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.